Shares of Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF – Get Rating) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $27.08 and last traded at $27.08, with a volume of 150 shares changing hands. The stock had previously closed at $24.62.
Separately, Zacks Investment Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $30.00 target price on the stock in a report on Tuesday, May 3rd.
The firm’s 50-day moving average is $25.73 and its 200-day moving average is $24.28. The company has a market capitalization of $13.92 billion, a PE ratio of 17.05 and a beta of 0.34.
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors.
- Get a free copy of the StockNews.com research report on Ono Pharmaceutical (OPHLF)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.